NEUARTIGE ALPHA4BETA7-DIMERANTAGONISTEN

Patent europeic · EP2906584 · Stritgà

Inscripziun en il register

Numer da publicaziun: EP2906584
Numer da la dumonda: EP13845982
Gener: Patent europeic cun effect per la Svizra ed il Liechtenstein
Status: Stritgà
Scrittira da patent: Concedì
Annunzià: 11-10-2013
Publitgà: 19-08-2015
Concedì: 20-11-2019
Stritgà: 31-10-2020
Motiv: Taxa annuala betg pajada
Classas IPC: A61K 38/00 (2006.01)
C07K 14/47 (2006.01)
C07K 14/705 (2006.01)
Prioritad: US 201261712722 P 11.10.2012
US 201361807714 P 02.04.2013
US 201314050349 10.10.2013
Dumonda PCT: PCT/US2013/064439 11.10.2013
Publicaziun PCT: WO2014/059213 17.04.2014
Lingua da l’annunzia: englais
Funtauna: Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

19-05-2021
Stritgà, taxa betg pajada
Published in Swissreg on 19.05.2021
20-11-2019
Concedì
Published in Swissreg on 20.11.2019

Partidas

Possessur

Protagonist Therapeutics, Inc.

Protagonist Therapeutics Inc.

521 Cottonwood Drive Suite A, Milpitas, California 95035, US

Inventur

MATTHEAKIS, Larry C.

Cupertino California 95014, US

BHANDARI, Ashok

Pleasanton California 94588, US

PATEL, Dinesh V.

Fremont California 94539, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.